MGNX
MacroGenics, Inc. Healthcare - Biotechnology Investor Relations →
MacroGenics, Inc. (MGNX) closed at $2.86 as of 2026-03-20, trading 41.9% below its 200-week moving average of $4.92. This places MGNX in the extreme value zone. The stock is currently moving closer to the line, down from -39.1% last week. With a 14-week RSI of 83, MGNX is in overbought territory.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (2.78 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 601 weeks of data, MGNX has crossed below its 200-week moving average 10 times. On average, these episodes lasted 44 weeks. The average one-year return after crossing below was -30.9%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $182 million, MGNX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -86.9%. The stock trades at 3.3x book value.
Share count has increased 2.6% over three years, indicating dilution.
Over the past 11.6 years, a hypothetical investment of $100 in MGNX would have grown to $14, compared to $402 for the S&P 500. MGNX has returned -15.8% annualized vs 12.8% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MGNX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MGNX Crosses Below the Line?
Across 10 historical episodes, buying MGNX when it crossed below its 200-week moving average produced an average return of -32.1% after 12 months (median -19.0%), compared to +6.3% for the S&P 500 over the same periods. 20% of those episodes were profitable after one year. After 24 months, the average return was -33.3% vs +19.2% for the index.
Each line shows $100 invested at the moment MGNX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MGNX has crossed below its 200-week MA 10 times with an average 1-year return of +-30.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2014 | Nov 2014 | 9 | 28.9% | +32.5% | -86.7% |
| Aug 2015 | Oct 2015 | 9 | 20.8% | +9.0% | -89.8% |
| Jan 2016 | Jul 2016 | 27 | 43.5% | -18.5% | -88.5% |
| Oct 2016 | Nov 2016 | 4 | 23.6% | -30.5% | -88.6% |
| Nov 2016 | Feb 2018 | 65 | 39.9% | -26.2% | -89.1% |
| Apr 2018 | May 2020 | 109 | 74.5% | -12.7% | -87.3% |
| Sep 2021 | Sep 2021 | 1 | 0.4% | -84.6% | -85.5% |
| Oct 2021 | Nov 2021 | 3 | 3.7% | -82.2% | -85.5% |
| Nov 2021 | Jan 2024 | 115 | 87.1% | -65.1% | -84.6% |
| May 2024 | Ongoing | 98+ | 87.8% | Ongoing | -13.6% |
| Average | 44 | — | +-30.9% | — |
Frequently Asked Questions
Is MGNX below its 200-week moving average?
Yes. As of 2026-03-20, MacroGenics, Inc. (MGNX) is trading 41.9% below its 200-week moving average of $4.92. The current price is $2.86.
What is MGNX's 200-week moving average price?
MacroGenics, Inc.'s 200-week moving average is $4.92 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MGNX drops below its 200-week moving average?
MGNX has crossed below its 200-week moving average 10 times in our data. The average one-year return after these crossings was -30.9%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 44 weeks on average.
Is MGNX a good value right now?
Here's what our data says about MGNX as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 83 (overbought). Free cash flow is currently negative. Return on equity is -86.9%. Price-to-book is 3.3x. This is not a buy or sell recommendation — always do your own research.
How does MGNX compare to the S&P 500?
Over the past 11.6 years, $100 invested in MGNX would have grown to $14, compared to $402 for the S&P 500. That's -15.8% annualized vs 12.8% for the index. MGNX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20